Cannabis Law and Access in Netherlands

The gap between tolerated and legal

Forty-odd years of Dutch cannabis policy and the world still misreads it. The Netherlands did not legalise cannabis. What it did was formalise a policy of gedoogbeleid , prosecutorial tolerance , that sits in the permanent grey space between prohibition and a regulated market. I spend most of my working week reading scheduling instruments and access law, so I find this particular legal construction genuinely interesting. It is not a workaround. It was a deliberate policy choice, and understanding the distinction matters if you want to understand why the Dutch model keeps generating reform pressure from within the Netherlands itself.

Australian readers: none of what follows is Australian law. Access to cannabis in Australia is governed by the Therapeutic Goods Administration, the Poisons Standard, and pathways like the Special Access Scheme and the Authorised Prescriber programme. The Dutch framework described here is purely for educational context.

What gedoogbeleid actually means

The Opium Act (Opiumwet) 1976 is the controlling statute. Cannabis , including the plant, resin, and preparations containing tetrahydrocannabinol (THC); sits on List II of the Opiumwet, which covers drugs considered less serious than those on List I. Possession, sale, and production of List II substances remain criminal offences under the Act. Full stop.

What the gedoogbeleid policy does is instruct prosecutors not to prosecute a specific, tightly bounded set of activities. The famous coffeeshop system exists because prosecutors agreed not to act, not because the law permits it. That is an important distinction. No Dutch court has ever found coffeeshop cannabis sales to be lawful; the courts have simply confirmed that the prosecutorial tolerance policy is itself lawful.

The tolerated activities are governed by the AHOJ-G criteria, an acronym for the conditions a coffeeshop must meet to avoid prosecution:

• A, no advertising (affichering)
• H; no hard drugs on premises (harddrugs)
• O, no nuisance (overlast)
• J, no sales to minors under 18 (jongeren)
• G; no large transactions; maximum 5 grams per person per visit (grote hoeveelheden)

Municipalities also control licensing. Amsterdam, Rotterdam, and other cities set their own coffeeshop numbers and conditions. Some municipalities, particularly in the south near the Belgian and German borders, banned coffeeshops entirely or reduced them significantly, partly in response to cross-border drug tourism. The city of Venlo, right on the German border, went through years of legal and political conflict over exactly this.

The supply problem: the back-door paradox

Here is where the model's internal tension becomes really clear. Retail sale at the front door of a coffeeshop is tolerated. Wholesale supply to coffeeshops; the back door, has never been tolerated, and cultivation for supply remains a criminal offence under the Opiumwet. So coffeeshops have legally operated in a state where the product they sell cannot legally reach them. Dutch policymakers have described this as the achterdeurprobleem: the back-door problem.

It is, honestly, a strange construction to sustain for forty years. The Dutch government has known about it the entire time. It has also generated real regulatory consequences: because supply operates outside any legal framework, there is no formal quality control, no standardised testing for pesticides or residual solvents, and no oversight of cannabinoid profiles, including the ratio of CBD to THC; in retail products.

The Experiment: regulated supply trials

The Wet experiment gesloten coffeeshopketen, the Closed Coffeeshop Chain Experiment Act, came into force in 2021. It is the Netherlands' attempt to address the back-door problem directly, by running a closed, regulated supply chain in a defined number of municipalities. Ten municipalities were selected initially, including Tilburg and Breda, with licensed growers supplying product only to participating coffeeshops in those regions.

The trial is ongoing. Licensed growers under the experiment operate under production and quality requirements that have no precedent in Dutch cannabis law; including documented cannabinoid content. This is genuinely new territory: for the first time, Dutch coffeeshop cannabis is being grown, tested, and supplied inside a legal framework rather than outside it.

The trial's findings are expected to inform whether the Netherlands moves toward broader regulated supply. The Office of the Experiment Closed Cannabis Chain (Bureau Experiment Gesloten Cannabisketen) is the responsible body, and its interim reporting has flagged both logistical challenges and what it describes as early indications of consumer participation in the participating municipalities. I'd treat any headline conclusions cautiously until the full evaluation period closes, interim data from regulatory pilots has a habit of being selectively quoted.

Medical cannabis: a separate, more orthodox framework

Separate from the coffeeshop system, the Netherlands has operated a medical cannabis programme since 2003. The Office of Medicinal Cannabis (Bureau voor Medicinale Cannabis, BMC), operating under the Ministry of Health, Welfare and Sport, oversees the cultivation and distribution of pharmaceutical-grade cannabis for medical use.

Prescriptions are issued by physicians. Product quality is subject to GMP-equivalent standards, closer to what Australians would recognise from the Good Manufacturing Practice requirements the TGA applies to registered therapeutic goods. Dispensing occurs through pharmacies. The cannabinoid profiles available through the medical programme; including varieties selected for their cannabidiol content alongside THC, are documented and standardised, unlike the coffeeshop supply chain.

The contrast between the medical and recreational frameworks is stark. One is a properly documented supply chain with quality controls. The other is a four-decade policy improvisation that the Dutch government is only now beginning to formalise.

Cannabis chemistry: what's in Dutch medical products

For readers interested in the chemistry: Dutch medical cannabis varieties are characterised by their cannabinoid and terpene profiles. THC is the primary psychoactive constituent, binding predominantly at CB1 receptors in the central nervous system. CBD does not bind with the same affinity at CB1, and its pharmacological behaviour involves multiple receptor systems, for a deeper look at that, see our endocannabinoid system glossary entry.

Terpene content; compounds like myrcene, beta-caryophyllene, and linalool, varies across varieties and contributes to the organoleptic and chemical characteristics of the product. Some researchers have investigated whether terpene-cannabinoid combinations produce different pharmacological effects compared to isolated cannabinoids; this is sometimes called the entourage effect hypothesis, though the evidence base remains preliminary and contested.

What this means for Australian context

I was out on a long Saturday ride through the Brindabellas a few weeks back, and a cycling mate asked me whether Australia could ever end up with something like the Dutch model. Short answer: the legal architecture is completely different. Australia operates under the Narcotic Drugs Act 1967 (Cth) and the Poisons Standard, where cannabis for non-medical use remains prohibited under federal law. Medicinal cannabis is accessed via prescription, classified as either Schedule 4 (low-THC products) or Schedule 8 (THC-containing products) under the Poisons Standard; through TGA-overseen pathways.

The Australian Capital Territory introduced personal possession decriminalisation in 2020, and some other states have decriminalisation provisions for minor possession offences. But decriminalisation is not legalisation, and it certainly is not a regulated supply framework. The Dutch experiment with regulated supply is worth watching precisely because it is generating real data on what a transition from tolerance to formal regulation looks like, data other jurisdictions will use to model their own policy options.

The gedoogbeleid model is not a template. It is a specific historical artefact of Dutch drug policy, sustained by political conditions that don't map cleanly onto anywhere else. But the supply-chain experiment now underway is something genuinely new, and the evidence coming out of it will be cited in policy debates for years.

Sources

• Toleration policy regarding soft drugs and coffee shops, Government of the Netherlands
• Cannabis knowledge base; Trimbos Institute (Netherlands Institute of Mental Health and Addiction)
• Cannabis policy in the Netherlands: recent developments, NCBI / PubMed Central
• Netherlands Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

, Marcus Hale, Regulatory researcher; TGA & access law